Friday, 29 August 2014

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study (Takeda)


Effects of the Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus (RAMP-DM) on biomedical outcomes, observed cardiovascular events and cardiovascular risks in primary care

The RAMP-DM resulted in greater improvements in HbA1c and reduction in observed and predicted cardiovascular risks at 12 months follow-up, which indicated a risk-stratification multidisciplinary intervention was an effective strategy for managing Chinese people with diabetes in the primary care setting (Cardiovascular Diabetology)


Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study

There are patients for whom glycaemic control worsens and a majority remained above the recommended level, suggesting an unmet need despite the availability of many OAD (BMC Endocrine Disorders)


Postpartum plasma C-peptide and ghrelin concentrations are predictive of type 2 diabetes in women with previous gestational diabetes mellitus

This is the first report that identifies C-peptide and ghrelin as potential biomarkers for the prediction of type 2 diabetes in women with a history of GDM (Journal of Diabetes)


Relationship between mid-trimester ultrasound fetal liver length measurements and gestational diabetes mellitus

Fetal liver length is strongly correlated with OGTT results, and could serve as a valid marker in prediction of GDM in high risk population (Journal of Diabetes)


Treatment of type 2 diabetes by free fatty acid receptor agonists 

In this review we show that FFA receptor agonism is a potential clinical target for T2D treatment and discuss ongoing drug development programs within industry and academia aimed at improving the safety and effectiveness of these potential treatments (Frontiers in Endocrinology)

Thursday, 28 August 2014

Endothelial cell autoantibodies in predicting declining renal function, end-stage renal disease, or death in adult type 2 diabetic nephropathy

These results suggest that anti-endothelial cell antibodies interact significantly with albuminuria in predicting the composite endpoint of death, ESRD, or substantial decline in renal function in older, adult type 2 diabetic nephropathy (Frontiers in Endocrinology)


Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus

PN is associated with increased risk for a first cardiovascular event among individuals with diabetes (Heart)





Wednesday, 27 August 2014

Quantification of the Glycemic Response to Microdoses of Subcutaneous Glucagon at Varying Insulin Levels

EGP increases steeply with glucagon doses between 25 and 175 µg at lower insulin infusion rates. However, high insulin infusion rates prevent these doses of glucagon from significantly increasing glucose output and may reduce glucagon effectiveness in preventing hypoglycemia when used in the artificial pancreas (Diabetes Care)


The control of blood pressure might be important in delaying progression of arterial aging in patients with type 2 diabetes mellitus

We found that the variation of blood pressure was associated with the progression of vascular aging of the large- to middle-sized arteries in patients with type 2 DM. Therefore, control of blood pressure might be important in reducing arterial aging or PWV in patients with type 2 DM (Clinical Interventions in Aging)


The prognosis of diabetic retinopathy in patients with type 2 diabetes since 1996–1998: the Skaraborg Diabetes Register

Most patients with diabetes develop little retinopathy for the first 10 years after diagnosis. High HbA1c at baseline was associated with retinopathy and maculopathy during follow-up. Antihypertensive treatment, probably a proxy for regular controls and early detection of diabetes, was associated with less retinopathy (International Ophthalmology)


Optical quality of the diabetic eye: a review

This review aims to provide an overview of current knowledge about the effects of diabetes mellitus in these optical phenomena and its consequence on the visual quality of the diabetic patient (Eye)

Monday, 25 August 2014

Hemoglobin A1c, comorbid conditions and all-cause mortality in older patients with diabetes: A retrospective 9-year cohort study

In our patient population, HbA1c scores<6.4% have significantly higher all-cause mortality. CHF is a major determinant of all-cause mortality. Adults with comorbid CHF and high HbA1c scores have lower all-cause mortality (Diabetes Research and Clinical Practice)


Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women

Long-term use of sulfonylureas was associated with a significantly higher risk of developing CHD among women with diabetes (Diabetes Care)


Diabetes Risk Among Overweight and Obese Metabolically Healthy Young Adults

Healthy metabolic profile and the absence of diabetes risk factors do not protect young adults from incident diabetes associated with overweight and obesity (Diabetes Care)

Friday, 22 August 2014

Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies

Metformin use was associated with a decreased risk of AF in patients with type 2 DM who were not using other anti-diabetic medication, probably via attenuation of atrial cell tachycardia-induced myolysis and oxidative stress (Cardiovascular Diabetology)


The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in Type 1 Diabetes

High levels of sE-selectin and PAI-1 are associated with the development of retinopathy in patients with uncomplicated type 1 diabetes (Diabetes and Its Complications)

Thursday, 21 August 2014

FDA allows marketing of first ZnT8Ab autoantibody test to help diagnose type 1 diabetes

Rhe first zinc transporter 8 autoantibody (ZnT8Ab) test that can help determine if a person has type 1 diabetes and not another type of diabetes (U.S. Food and Drug Administration)

Wednesday, 20 August 2014

Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders

Our results show that metformin may reduce cancer incidence and mortality in patients with diabetes However, the reduction seems to be of modest magnitude and not affecting all populations equally (Cancer Prevention Research)


Mitsubishi Tanabe and AstraZeneca announce research collaboration in diabetic nephropathy

The three-year research collaboration will develop small molecule candidates from their respective portfolios (Mitsubishi Tanabe)


U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes

INVOKAMET™ is the first fixed-dose combination of an SGLT2 inhibitor with metformin approved in the United States (Janssen)


Stress Hyperglycaemia in Hospitalised Patients and Their 3-Year Risk of Diabetes: A Scottish Retrospective Cohort Study

Plasma glucose measured during an emergency hospital admission predicts subsequent risk of developing type 2 diabetes (PLoS Medicine)

Tuesday, 19 August 2014

Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes

Correct injection site rotation appears to be the critical factor in preventing LH, which is associated with reduced glucose variability, hypoglycaemia, insulin consumption and costs (Diabetes & Metabolism)


Depression, anxiety and self-care behaviours of young adults with Type 2 diabetes: results from the international Diabetes Management and Impact for Long-term Empowerment and Success (MILES) Study

Our results suggest that Type 2 diabetes is as challenging as Type 1 diabetes for young adults and more so than for older adults. Young adults with Type 2 diabetes may require more intensive psychological and self-care support than their older counterparts (Diabetic Medicine)


Reversal of Type 2 diabetes after bariatric surgery is determined by the degree of achieved weight loss in both short- and long-duration diabetes

The study shows that the degree of achieved weight loss is the major determinant of return to normal blood glucose levels after bariatric surgery (Diabetic Medicine)


Assessment of the Relative Effectiveness and Tolerability of Treatments of Type 2 Diabetes Mellitus: A Network Meta-analysis

Our results point out the relative superiority of 2- and 3-drug combination regimens over metformin and summarize treatment effects and tolerability in a comprehensive manner, which adds to our knowledge regarding T2DM treatment options (Clinical Therapeutics)


Systolic blood pressure as a predictor of incident albuminuria and rapid renal function decline in type 2 diabetic patients

In addition to baseline UACR, SBP is one of the most powerful modifiable independent risk factors for incident albuminuria and a rapid renal function decline in type 2 diabetic patients without symptomatic cardiovascular disease (Diabetes and Its Complications)


Relationship between gut hormones and glucose homeostasis after bariatric surgery

Current data reinforce the hypothesis that T2D reversion after bariatric surgery may be related to glycemic homeostasis developed by the intestine (Diabetology & Metabolic Syndrome)

Monday, 18 August 2014

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection)

The U.S. Food and Drug Administration granted tentative approval for Basaglar™ (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes (Lilly)

Thursday, 14 August 2014

Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985—2011

Continued increases in the incidence of diagnosed diabetes combined with declining mortality have led to an acceleration of lifetime risk and more years spent with diabetes, but fewer years lost to the disease for the average individual with diabetes (The Lancet Diabetes & Endocrinology)


Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes

A secondary analysis of the Look AHEAD randomised clinical trial (The Lancet Diabetes & Endocrinology)


Development of a New Diabetes Risk Prediction Tool for Incident Coronary Heart Disease Events

This new CHD risk estimator has better discriminative ability for incident CHD than the FRS, UKPDS, and the ATP III/NCEP recommendations in a multi-ethnic cohort with T2DM (Atherosclerosis)

Wednesday, 13 August 2014

Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach

This accessible and easy to use algorithm may help physicians to choose a personalized treatment plan for each patient and to optimize it in a timely manner, thereby lessening clinical inertia (Pharmacogenomics and Personalized Medicine)

Tuesday, 12 August 2014

Prescribing for Diabetes, England - 2005-06 to 2013-14

This is the latest in a series of annual reports published by the Health and Social Care Information Centre on Prescribing for Diabetes in England, within primary care (HSCIC)


Education and technology used to improve the quality of life for people with diabetes mellitus type II

Findings suggest the importance of the role of care providers in emphasizing the implications of poor self-management strategies; that a multidisciplinary approach may enhance the education process; and a need for further developments in technology to address DMT2 self-management strategies (Journal of Multidisciplinary Healthcare)

Monday, 11 August 2014

Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin

Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015 (MannKind)


Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on ß-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis

The glucose-lowering efficacy of DPP-4 inhibitors was greater in Asian patients than in Caucasian patients, although the effect on ß-cell function was inferior in Asian patients. The effect of DPP-4 inhibitors on insulin resistance and body weight in Asian patients was comparable with that observed in Caucasian patient (Journal of Diabetes)


Low dose of acetylsalicylic acid and oxidative stress-mediated endothelial dysfunction in diabetes: a short-term evaluation

Our findings suggest that ASA utilization for primary prevention in diabetic patients causes a significant increase of oxidative stress burden impairing the vascular function. Present data, if confirmed on a larger population, could permanently discourage the use of the ASA for the primary prevention in patients with DM (Acta Diabetologica)


Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies

Metformin use was associated with a decreased risk of AF in patients with type 2 DM who were not using other anti-diabetic medication, probably via attenuation of atrial cell tachycardia-induced myolysis and oxidative stress (Cardiovascular Diabetology)

Friday, 8 August 2014

Topical application of the bee hive protectant propolis is well tolerated and improves human diabetic foot ulcer healing in a prospective feasibility study

Topical propolis is a well-tolerated therapy for wound healing and this pilot in human DFU indicates for the first time that it may enhance wound closure in this setting when applied weekly. A multi-site randomized controlled of topical propolis now appears to be warranted in diabetic foot ulcers (Diabetes and Its Complications)


Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Center-Involved Diabetic Macular Edema

Disorganization of the retinal inner layers in the 1-mm foveal area is associated with VA, and change in DRIL predicts future change in VA. Early change in DRIL prospectively identifies eyes with a high likelihood of subsequent VA improvement or decline (JAMA Ophthalmology)

Thursday, 7 August 2014

First Non-Injectable GLP-1 Analog for Type-2 Diabetes

Aegis Offers Exclusive License for Patented Exenatide Metered Nasal Spray (Aegis Therapeutics)


Three-graded stratification of carbohydrate restriction by level of baseline hemoglobin A1c for type 2 diabetes patients with a moderate low-carbohydrate diet

Three-graded stratification of carbohydrate restriction according to baseline HbA1c levels may provide T2DM patients with optimal objectives for carbohydrate restriction and prevent restriction from being unnecessarily strict (Nutrition & Metabolism)

Wednesday, 6 August 2014

Glucose Counterregulation in Advanced Type 2 Diabetes Mellitus: Effect of ß-Adrenergic Blockade

Overall glucose counterregulation is preserved in advanced T2DM, but the contribution of EGP is diminished. ß-Adrenergic blockade may increase insulin sensitivity at normoglycemia but does not impair glucose counterregulation in T2DM patients, even those with advanced ß-cell failure (Diabetes Care)

Tuesday, 5 August 2014

Once-Weekly Exenatide as Adjunct Treatment of Type 1 Diabetes Mellitus in Patients Receiving Continuous Subcutaneous Insulin Infusion Therapy

This study revealed that the addition of once-weekly exenatide to insulin therapy for type 1 diabetes patients leads to significant improvements in A1C, body weight, body mass index and insulin doses (Canadian Journal of Diabetes)

Friday, 1 August 2014

FDA approves Jardiance to treat type 2 diabetes

The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes

Annual diabetes checks among indicators proposed for latest NICE QOF menu

A series of annual checks to monitor and improve the health of people with diabetes are among measures proposed by NICE for its latest Quality and Outcomes Framework (QOF) indicator menu (NICE)


Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial

Raised glucose concentration is a modifiable risk factor for ischaemic heart disease in middle-aged people with type 2 diabetes and other cardiovascular risk factors (The Lancet Diabetes & Endocrinology)


High or low calcium intake increases cardiovascular disease risks in older patients with type 2 diabetes

Patients whose Ca intake was high or low (81.2%) had significantly higher C-reactive protein (CRP) than those whose Ca intake was moderate (Cardiovascular Diabetology)


New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Gla-300 controls HbA1c as well as Gla-100 for people with type 2 diabetes treated with basal and mealtime insulin, but with consistently less risk of nocturnal hypoglycemia (Diabetes Care)


Comparison of the effects on glycaemic control and ß-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study)

All three agents showed efficacy regarding glycaemic control and metabolic benefits; however, exenatide showed the greatest efficacy. ß-cell function improved in all treatment groups, hence early initiation of ß-cell-protective therapy may halt the decline in ß-cell function in type 2 diabetes (Journal of Internal Medicine)